坎地沙坦酯

坎地沙坦酯片治疗原发性高血压118例

Candesartan cilexetil in treatment of essential hypertension in 118 patients

目的观察坎地沙坦酯片治疗1、2级原发性高血压的临床疗效及其安全性。

Aim To investigate the clinical efficacy and security of candesartan cilexetil tablets in treatment of 1 ~ 2 grade essential hypertension .

抗乙肝新药Entecavir及抗高血压新药ALK重要中间体的合成研究抗高血压药坎地沙坦酯的新合成方法

Synthesis of the New Anti-HBV Agent Entecavir and the Key Intermediate of the New Antihypertensive Agent ALK ; A novel synthesis of antihypertensive drug candesartan cilexitil

坎地沙坦酯对原发性高血压患者尿微量白蛋白的影响

Effects of Candesartan Cilexetil on Urine Microalbuminuria in Patients with Essential Hypertension

2种坎地沙坦酯制剂的人体生物等效性研究

Studies on the Bioequivalence of Two Candesartan Cilexetil Preparations

本研究提出一条全新的，有效的坎地沙坦酯避专利合成路线和一条新颖的，高效的替米沙坦的合成路线。

The research suggested a novel and effective route for synthesis of candesartan cilexetil and telmisartan respectively .

坎地沙坦酯组、苯磺酸氨氯地平组、联合用药组的不良反应发生率分别为10.8%，16.1%，和16.2%（P>0.05）。

Occurrence rates of the bad reaction of 3 groups were 10.8 % , 16.1 % , and 16.2 % ( P > 0.05 ) .